It is our working hypothesis that mutations and altered expression of RB, p53, and PTEN, or those affectingregulatory genes involved in these pathways, produce a selective advantage for tumor growth andaggressive behavior in patients with soft tissue sarcomas (STS). This hypothesis will be tested by anintegrated approach, analyzing human tumor samples and conducting genetic studies that includegeneration of in vitro and in vivo models.
Aim 1. To define the clinical and biological implications of RBinactivation for proliferation and genomic stability in STS. We will characterize RB mutations, altered patternsof pRB and E2F1 expression, as well as upstream regulators (cyclin D, Cdk4). We will also assess Mad2expression, an E2F1 transcriptional target that when deregulated causes chromosome instability andaneuploidy. We will assess the consequences of RB inactivation, identifying up- and down-regulated targetsby high throughput studies.
Aim 2. To characterize molecular alterations affecting the p53 pro-apoptoticresponse and define their clinical significance in STS. We will conduct a systematic characterization of TP53mutations and p53 expression using a combination of methods. We will analyze regulatory events of the p53pathway, focusing on Hdm2 and p14/Arf expression. We will study p53 apoptotic signaling, centering on Baxand Bcl-2, PUMA and NOXA, defining their impact on tumor progression and lack of response to particulartreatments. The mechanistic consequences of p53 inactivation will be evaluated using functional assays.
Aim 3. To determine the molecular mechanisms of tumor suppression by the Pten pathway in STS. We willestablish the clinical relevance of detecting PTEN mutations and altered Pten expression. We will investigatethe impact of downstream events, such as activation of Akt, mTOR and elF4E, as they participate insarcomagenesis and STS progression. In addition, we are generating murine models to determine whetherinactivation of Rb, p53 and Pten are required and cooperate for sarcoma development and progression. Ourmain objectives include: i) to assess the basis of the functional crosstalk between RB, p53, and PTENpathways in tumor suppression; and ii) to translate basic and medical research findings into clinically appliedstudies. Our final translational goal is to produce a paradigm shift in clinical practice by incorporatingbiomarkers as robust decision tools to better guide the management of STS patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA047179-15A2
Application #
7141201
Study Section
Subcommittee G - Education (NCI)
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
15
Fiscal Year
2006
Total Cost
$133,801
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2017) Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1. Genes Chromosomes Cancer 56:42-50
Seifert, Adrian M; Zeng, Shan; Zhang, Jennifer Q et al. (2017) PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res 23:454-465
Argani, Pedram; Zhang, Lei; Reuter, Victor E et al. (2017) RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol 41:655-662
Argani, Pedram; Zhong, Minghao; Reuter, Victor E et al. (2016) TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 40:723-37
Tan, Marcus C B; Brennan, Murray F; Kuk, Deborah et al. (2016) Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg 263:593-600
Specht, Katja; Zhang, Lei; Sung, Yun-Shao et al. (2016) Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40:433-42
Huang, Shih-Chiang; Ghossein, Ronald A; Bishop, Justin A et al. (2016) Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. Am J Surg Pathol 40:51-9
Dickson, Mark A; Schwartz, Gary K; Keohan, Mary Louise et al. (2016) Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2:937-40

Showing the most recent 10 out of 336 publications